Sinovac Biotech rejects ‘deceptive, illegal’ claims by SAIF

The Board of Directors of SINOVAC Biotech (SVA) Ltd. said in a statement that it “categorically rejects the recent deceptive and illegal claims by SAIF and the Imposter Former Board that it purported to ‘reconvene’ the adjourned Special Meeting of Shareholders and announced sham voting results of the shareholder proposals.” SINOVAC says: “At the July 8, 2025 Special Meeting, SINOVAC Chairman Chiang Li validly adjourned the meeting, to preserve the integrity of the Special Meeting and protect shareholder interests, pending the resolution of litigation in Antigua related to the validity of the 11.8 million shares purportedly issued following an invalid private investment in public equity to Advantech/Prime and Vivo Capital. SINOVAC shareholders should ignore SAIF’s lies. SAIF and the Imposter Former Board did NOT have the authority or any legal basis to “reconvene” the Special Meeting following the valid adjournment. SAIF’s self-declaration of a final tally of shareholder votes was a complete sham. SINOVAC is evaluating its legal remedies with respect to the deceptive and unlawful conduct of SAIF and the Imposter Former Board, including with authorities in Antigua and the United States… The rightful SINOVAC Board remains in place and will continue to govern the Company. The Board has a duty to implement the UK Privy Council’s judgment and order, which includes resolving the question of the validity of the PIPE shares. The Board will continue to fight on behalf of all SINOVAC shareholders and remains committed to its mission of restoring fairness, delivering value and protecting the rights of all valid shareholders.”